Natco Pharma (NATCOPHARM) Share News & Alerts

Natco Pharma, Lupin alliance secures U.S. FDA nod for generic breast cancer drug

▲ Bullish +0.05%

The US FDA approval for the bioequivalent version of Halaven injection expands Natco Pharma's high-margin oncology portfolio in the US market. Given that Halaven has annual US sales of around 43.7 million USD, this targeted entry into a niche, limited-competition product will generate a dependable revenue stream. Expect a bullish structural shift for the stock over a multi-week to multi-month swing trading horizon.

Stock Picks Today: Dixon Tech, Natco Pharma, Ather Energy, NMDC And More On Brokerages' Radar

▲ Bullish +1.06%

Investec raised its target price to Rs 1,220 on strong underlying core performance and clear M&A optionality backed by a robust Rs 2,500 crore cash reserve. This positive guidance upward revision creates strong structural demand, likely keeping the trend bullish for positional investors.

Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit

▼ Bearish +5.07%

The stock is reacting to mixed analyst views on its current valuation and chart patterns, limiting the impact to immediate support/resistance levels.

Stock Market News Today Live Updates: Nifty, Sensex Erase Gains; Inox Wind, Natco Pharma Slump Up To 7%

▼ Bearish +6.41%

Natco Pharma faces a sharp downward structural re-rating following dismal Q4 earnings that showed a 34% drop in net profit alongside contracting operating margins. Positional traders are likely to remain bearish on the stock across multiple weeks as the market prices in the sudden break in its historical operational efficiency.

Natco Pharma Q4 net slips 34% to ₹269 cr. on formulation exports, shares fall 13.5%

▼ Bearish +12.79%

The sharp 34% drop in net profit and a steep contraction in EBITDA margins due to lower formulations export sales directly trigger aggressive selling pressure. Given that the results missed analyst expectations significantly and guidance highlights a muted FY2027, the stock is likely to undergo a multi-week positional correction or consolidation phase.

Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoY

▼ Bearish +12.79%

The stock is experiencing a sharp sell-off due to a severe miss in Q4 earnings, where net profit dropped 34% alongside weak revenues and margins. This disappointing operational performance damages near-term investor confidence, likely leading to a sustained multi-day or multi-week bearish trend for swing and positional traders as analysts revise their targets downward.

Natco Pharma tanks after Q4 profit declines 34% YoY to Rs 268 cr

▼ Bearish +12.79%

The stock is experiencing a severe multi-day sell-off after Q4 net profits missed Street expectations, declining 34% YoY alongside a massive contraction in EBITDA margins down to 17.2%. Given that the lower earnings directly impair the valuation base for FY27 and include non-operational tax adjustments, swing traders are likely to maintain short positions or avoid the stock as institutional earnings cuts trigger further mechanical selling over the upcoming weeks.

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 15 May 2026

▲ Bullish +1.69%